142 related articles for article (PubMed ID: 22683289)
1. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Owen K; Cross DM; Derzi M; Horsley E; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan.
Cross DM; Derzi M; Horsley E; Owen K; Stavros FL
Regul Toxicol Pharmacol; 2012 Oct; 64(1):43-50. PubMed ID: 22683288
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of reproductive and developmental toxicity of sitaxentan (thelin) in rats.
Cross DM; Horsley E; Derzi M; Owen K; Stavros FL
Birth Defects Res B Dev Reprod Toxicol; 2012 Oct; 95(5):327-36. PubMed ID: 22890981
[TBL] [Abstract][Full Text] [Related]
4. Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry.
Erve JC; Gauby S; Maynard JW; Svensson MA; Tonn G; Quinn KP
Chem Res Toxicol; 2013 Jun; 26(6):926-36. PubMed ID: 23721565
[TBL] [Abstract][Full Text] [Related]
5. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
[No Abstract] [Full Text] [Related]
6. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
7. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
[TBL] [Abstract][Full Text] [Related]
8. Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
Pulido T; Sandoval J; Roquet I; Gutiérrez R; Rueda T; Peña H; Santos E; Miranda MT; Lupi E
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():14-8. PubMed ID: 19335742
[TBL] [Abstract][Full Text] [Related]
9. NTP technical report on the toxicology and carcinogenesis studies of 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (Gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 May; (529):4-168. PubMed ID: 16835634
[TBL] [Abstract][Full Text] [Related]
10. NTP toxicology and carcinogenesis studies of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (CAS No. 57465-28-8) in female Harlan Sprague-Dawley rats (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Jan; (520):4-246. PubMed ID: 16628245
[TBL] [Abstract][Full Text] [Related]
11. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists.
Kenna JG; Stahl SH; Eakins JA; Foster AJ; Andersson LC; Bergare J; Billger M; Elebring M; Elmore CS; Thompson RA
J Pharmacol Exp Ther; 2015 Feb; 352(2):281-90. PubMed ID: 25467130
[TBL] [Abstract][Full Text] [Related]
12. Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Faruqi S; Fathi H; Morice AH
Int J Cardiol; 2010 Oct; 144(3):e43-5. PubMed ID: 19171388
[TBL] [Abstract][Full Text] [Related]
13. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Galiè N; Hoeper MM; Gibbs JS; Simonneau G
Eur Respir J; 2011 Feb; 37(2):475-6. PubMed ID: 21282816
[No Abstract] [Full Text] [Related]
14. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.
Lavelle A; Sugrue R; Lawler G; Mulligan N; Kelleher B; Murphy DM; Gaine SP
Eur Respir J; 2009 Sep; 34(3):770-1. PubMed ID: 19720812
[No Abstract] [Full Text] [Related]
15. Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
Kähler CM; Graziadei I; Vogelsinger H; Desole S; Cima K; Vogel W
Wien Klin Wochenschr; 2011 Apr; 123(7-8):248-52. PubMed ID: 21451953
[TBL] [Abstract][Full Text] [Related]
16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
17. Toxicology and carcinogenesis studies of 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) (Cas No. 57117-31-4) in female Harlan Sprague-Dawley rats (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Sep; (525):1-198. PubMed ID: 17160103
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Cacoub P; Amoura Z; Langleben D
Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
[TBL] [Abstract][Full Text] [Related]
19. NTP technical report on the toxicity studies of methacrylonitrile (CAS No. 126-98-7). Administered by gavage to F344/N rats and B6C3F1 mice.
Ghanayem BI
Toxic Rep Ser; 2000 May; (47):1-56, A1-E6. PubMed ID: 11803706
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
